Pharma calls for Australian version of early access, adaptive licensing schemes
This article was originally published in SRA
Australia's Therapeutic Goods Administration should take steps to align its drug approval processes with those of the major overseas regulators and launch new product registration pathways that would allow patients to have earlier access to medicines in areas of high unmet needs or to drugs representing significant medical innovation1.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.